Trial Profile
A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as three doses of 120 mg or 180 mg (given as 2 injections of 60 mg or 90 mg on Day 1, repeated on Days 2 and 3) in patients with advanced prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2011
Price :
$35
*
At a glance
- Drugs Teverelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ardana plc
- 22 Jul 2011 New trial record